

HE Dr. Anvar Valiyevich Alimov
The Minister of Health
Ministry of Health
Navoi Str. 12
700011 Tashkent
The Republic of Uzbekistan

15 December 2016

Decision Letter: Request for 2017 Renewal of Gavi vaccine support

Your Excellency,

I am writing in relation to Uzbekistan's request for renewal of the New Vaccine Support (NVS) for Pneumococcal Vaccine, Pentavalent Vaccine and Rotavirus Vaccine that was reviewed by Gavi Managing Directors' Review on 18 of October 2016.

Following the recommendations made by the Managing Directors' Review, I am pleased to inform you that Gavi has **approved** Uzbekistan's request to renew Gavi vaccine support for 2017, subject to several conditions and requirements as specified in the Appendices to this letter.

The Appendices include the following important information:

- Appendix A: Financial and Programmatic information –Support for Pneumococcal Vaccine (PCV)
- Appendix B: Financial and Programmatic information –Support for Pentavalent Vaccine
- Appendix C: Financial and Programmatic information –Support for Rotavirus Vaccine
- Appendix D: Financial and Programmatic information –Support for Injection Safety Devices
- Appendix E: Recommendations of the Managing Directors' Review

Please do not hesitate to contact my colleague Ms Nilgun Aydogan at naydogan@gavi.org if you have any questions or concerns.

Yours sincerely,



Hind Khatib-Othman
Managing Director, Country Programmes

cc: The Minister of Finance
The Director of Medical Services
Director Planning Unit, MoH
The EPI Manager
WHO Country Representative



UNICEF Country Representative
Regional Working Group
WHO HQ
UNICEF Programme Division
UNICEF Supply Division

Decision Letter Uzbekistan - Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Uzbekistan					
2. Grant number: 1719-UZB-12c-X					
3. Date of Decision Letter: 15/12/2016					
4. Date of the Partnership Framework Agreement: 07/02/2014					
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine					
6. Vaccine type: Pneumococcal					
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 1 dose(s) per vial , LIQUID					
8. Programme duration¹: 2015 - 2019					
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)					
	2015-2016	2017	2018	2019	Total²
Programme Budget (US\$)	9,751,165 ³	5,423,500	3,798,000	2,774,500	21,747,165
10. Vaccine introduction grant (in US\$): Not applicable.					
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴					
Type of supplies to be purchased with Gavi funds in each year	2015-2016	2017			
Number of Pneumococcal vaccines doses		1,380,900			
Annual Amounts (US\$)	US\$9,751,165⁵	US\$5,423,500			
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.					
13. Self-procurement: Not applicable.					
14. Co-financing obligations: Reference code: 1719-UZB-12c-X-C According to the co-financing policy, the Country falls within the group Accelerated transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.					
Type of supplies to be purchased with Country funds in each year	2017	2018	2019		
Number of vaccine doses	937,400	1,297,200	1,716,600		
Number of AD syringes	1,021,600				
Number of safety boxes	11,250				
Value of vaccine doses (US\$)	US\$3,093,334				
Total co-financing payments (US\$) (including freight)	US\$3,292,000	US\$4,556,000	US\$6,028,500		
15. Operational support for campaigns: Not applicable					
16. Additional reporting requirements: Not applicable					

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.


³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

Reports and other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 15 December 2016

**Decision Letter
Uzbekistan - Support for Pentavalent Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Uzbekistan				
2. Grant number: 1718-UZB-04c-X				
3. Date of Decision Letter: 15/12/2016				
4. Date of the Partnership Framework Agreement: 07/02/2014				
5. Programme title: New Vaccine Support (NVS) - Pentavalent Routine				
6. Vaccine type: Pentavalent				
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID				
8. Programme duration⁶: 2009 - 2018				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2009-2016	2017	2018	Total⁷
Programme Budget (US\$)	31,152,557 ⁸	775,500	481,500	32,409,557
10. Vaccine introduction grant (in US\$): Not applicable.				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁹				
Type of supplies to be purchased with Gavi funds in each year	2009-2016	2017		
Number of Pentavalent vaccines doses			647,500	
Annual Amounts (US\$)	US\$31,152,557¹⁰	US\$775,500		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable.				
14. Co-financing obligations: Reference code: 1719-UZB-04c-X-C According to the co-financing policy, the Country falls within the group Accelerated transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.				
Type of supplies to be purchased with Country funds in each year	2017	2018		
Number of vaccine doses	1,756,500	2,041,000		
Number of AD syringes	1,740,900			
Number of safety boxes	19,175			
Value of vaccine doses (US\$)	US\$2,059,052			
Total co-financing payments (US\$) (including freight)	US\$2,190,000	US\$2,544,500		
15. Operational support for campaigns: Not applicable				
16. Additional reporting requirements: Not applicable				
Reports and other information				Due dates

⁶ This is the entire duration of the Programme.

⁷ This is the total amount endorsed by Gavi for the entire duration of the Programme.

⁸ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁹ This is the amount that Gavi has approved.

¹⁰ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2017
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi
 Hind Khatib-Othman
 Managing Director, Country Programmes
 15 December 2016

**Decision Letter
Uzbekistan - Support for Rotavirus Vaccine**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Uzbekistan				
2. Grant number: 1718-UZB-13b-X				
3. Date of Decision Letter: 15/12/2016				
4. Date of the Partnership Framework Agreement: 07/02/2014				
5. Programme title: New Vaccine Support (NVS) - Rotavirus Routine				
6. Vaccine type: Rotavirus				
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule				
8. Programme duration¹¹: 2014 - 2018				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2014-2016	2017	2018	Total¹²
Programme Budget (US\$)	5,925,285 ¹³	1,210,500	645,000	7,780,785
10. Vaccine introduction grant (in US\$): Not applicable.				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ¹⁴				
Type of supplies to be purchased with Gavi funds in each year	2014-2016	2017		
Number of Rotavirus vaccines doses			537,000	
Annual Amounts (US\$)	US\$5,925,285¹⁵	US\$1,210,500		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: Not applicable.				
14. Co-financing obligations: Reference code: 1719-UZB-13b-X-C According to the co-financing policy, the Country falls within the group Accelerated transition. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.				
Type of supplies to be purchased with Country funds in each year	2017	2018		
Number of vaccine doses	954,000	1,195,500		
Value of vaccine doses (US\$)	US\$2,086,668			
Total co-financing payments (US\$) (including freight)	US\$2,142,500	US\$2,688,000		
15. Operational support for campaigns: Not applicable				
16. Additional reporting requirements: Not applicable				
Reports and other information				Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.				15 May 2017

¹¹ This is the entire duration of the Programme.

¹² This is the total amount endorsed by Gavi for the entire duration of the Programme.


¹³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

¹⁴ This is the amount that Gavi has approved.

¹⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
17. Financial clarifications: Not applicable.	
18. Other conditions: Not applicable.	

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
15 December 2016

**Decision Letter
Uzbekistan - Support for Injection safety devices**

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: The Republic of Uzbekistan				
2. Grant number: 17-UZB-32a-X; 18-UZB-32a-X; 19-UZB-32a-X;				
3. Date of Decision Letter: 15/12/2016				
4. Date of the Partnership Framework Agreement: 07/02/2014				
5. Programme title: Injection Safety Devices ¹⁶				
6. Programme duration¹⁷: 2017 - 2019				
7. Programme Budget (indicative): (subject to the terms of the partnership framework agreement, if applicable)				
	2017	2018	2019	Total¹⁸
Programme Budget (US\$)	126,000	71,500	30,000	227,500
8. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ¹⁹				
TOTAL immunisation supplies to be purchased with Gavi funds in each year				2017
Number of AD syringes				2,493,800
Number of safety boxes				27,475
Annual Amounts for immunisation supplies for all Gavi vaccines (US\$)				126,000
Immunisation supplies to be purchased with Gavi funds in each year, by type of support				
New Vaccine Support (NVS), Pneumococcal (PCV13), 1 dose(s) per vial LIQUID,Routine				2017
Number of AD syringes				1,504,900
Number of re-constitution syringes				
Number of safety boxes				16,575
Annual Amounts for immunisation supplies for Vaccine (US\$)				76,000
New Vaccine Support (NVS), DTP-HepB-Hib, 10 dose(s) per vial, LIQUID,Routine				2017
Number of AD syringes				642,300
Number of safety boxes				7,075
Annual Amounts for immunisation supplies for Vaccine (US\$)				32,500
New Vaccine Support (NVS), Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID,Routine				2017
Number of AD syringes				346,600
Number of safety boxes				3,825
Annual Amounts for immunisation supplies for Vaccine (US\$)				17,500

¹⁶ This does not include vaccines.

¹⁷ This is the entire duration of the Programme.

¹⁸ This is the total amount endorsed by Gavi for the entire duration of the Programme.

¹⁹ This is the amount that Gavi has approved.

9. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.
10. Self-procurement: Not applicable.
11. Co-financing obligations: Co-financing requirements are listed in the relevant vaccine Decision Letter.

Signed by,

Hind Khatib

On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
15 December 2016

The MDs, following their deliberations:

- Recommended to the CEO:

Programme	Recommendation	Period	Indicative amount to be paid by Gavi
NVS – <i>PCV</i> in existing presentation	Extension	2017-2019	US\$ 5,423,500
NVS – <i>Pentavalent</i> in existing presentation	Extension	2017-2018	US\$ 775,500
NVS – <i>Rotavirus</i> in existing presentation	Extension	2017-2018	US\$ 1,210,500